In the period 2018-2019, 2021, it was estimated that U.S. men aged 65 to 84 years and older had a 10.6 percent chance of developing prostate cancer. This statistic shows the probability of males in the United States developing prostate cancer in 2018-2019, 2021, by age.

This dataset contains Cancer Incidence data for Prostate Cancer(All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for males segmented age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

From 2018 to 2022, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2018 and 2022, by age.

The graph presents prostate cancer relative survival rates in the U.S. from 2001 to 2016, showing 1-year, 5-year, and 10-year relative survival percentages based on age groups. The x-axis represents age groups, while the y-axis indicates survival rates at different time intervals. Survival rates remain high across all age groups, with patients aged 65–69 having the highest 10-year survival rate of 99.5%. In contrast, men aged 80 and older have the lowest survival rates, with 92.1% at 1 year and 82.7% at 10 years. The data highlights that younger patients generally experience better long-term survival outcomes.

From 2017 to 2021, around 42 percent of prostate cancer cases in the United States were among men aged 65 to 74 years. During that period, the median age at diagnosis for prostate cancer was 67 years. This statistic shows the distribution of prostate cancer cases in the United States in the period 2017-2021, by age.

Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

ObjectiveUsing the latest cohort study of prostate cancer patients, explore the epidemiological trend and prognostic factors, and develop a new nomogram to predict the specific survival rate of prostate cancer patients.MethodsPatients with prostate cancer diagnosed from January 1, 1975 to December 31, 2019 in the Surveillance, Epidemiology, and End Results Program (SEER) database were extracted by SEER stat software for epidemiological trend analysis. General clinical information and follow-up data were also collected from 105 135 patients with pathologically diagnosed prostate cancer from January 1, 2010 to December 1, 2019. The factors affecting patient-specific survival were analyzed by Cox regression, and the factors with the greatest influence on specific survival were selected by stepwise regression method, and nomogram was constructed. The model was evaluated by calibration plots, ROC curves, Decision Curve Analysis and C-index.ResultsThere was no significant change in the age-adjusted incidence of prostate cancer from 1975 to 2019, with an average annual percentage change (AAPC) of 0.45 (95% CI:-0.87~1.80). Among the tumor grade, the most significant increase in the incidence of G2 prostate cancer was observed, with an AAPC of 2.99 (95% CI:1.47~4.54); the most significant decrease in the incidence of G4 prostate cancer was observed, with an AAPC of -10.39 (95% CI:-13.86~-6.77). Among the different tumor stages, the most significant reduction in the incidence of localized prostate cancer was observed with an AAPC of -1.83 (95% CI:-2.76~-0.90). Among different races, the incidence of prostate cancer was significantly reduced in American Indian or Alaska Native and Asian or Pacific Islander, with an AAPC of -3.40 (95% CI:-3.97~-2.82) and -2.74 (95% CI:-4.14~-1.32), respectively. Among the different age groups, the incidence rate was significantly increased in 15-54 and 55-64 age groups with AAPC of 4.03 (95% CI:2.73~5.34) and 2.50 (95% CI:0.96~4.05), respectively, and significantly decreased in ≥85 age group with AAPC of -2.50 (95% CI:-3.43~-1.57). In addition, age, tumor stage, race, PSA and gleason score were found to be independent risk factors affecting prostate cancer patient-specific survival. Age, tumor stage, PSA and gleason score were most strongly associated with prostate cancer patient-specific survival by stepwise regression screening, and nomogram prediction model was constructed using these factors. The Concordance indexes are 0.845 (95% CI:0.818~0.872) and 0.835 (95% CI:0.798~0.872) for the training and validation sets, respectively, and the area under the ROC curves (AUC) at 3, 6, and 9 years was 0.7 or more for both the training and validation set samples. The calibration plots indicated a good agreement between the predicted and actual values of the model.ConclusionsAlthough there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.

From 2003 to 2017, there were around 485 new cases of prostate cancer per 100,000 men aged 60 to 64 years in the United States. This statistic illustrates the rate of new prostate cancer cases in the United States from 2003 to 2017 by age, per 100,000 men.

IntroductionSociodemographic disparities in genitourinary cancer-related mortality have been insufficiently studied, particularly across multiple cancer types. This study aimed to investigate gender, racial, and geographic disparities in mortality rates for the most common genitourinary cancers in the United States.MethodsMortality data for prostate, bladder, kidney, and testicular cancers were obtained from the Centers for Disease Control and Prevention (CDC) WONDER database between 1999 and 2020. Age-adjusted mortality rates (AAMRs) were analyzed by year, gender, race, urban–rural status, and geographic region using a significance level of p < 0.05.ResultsOverall, AAMRs for prostate, bladder, and kidney cancer declined significantly, while testicular cancer-related mortality remained stable. Bladder and kidney cancer AAMRs were 3–4 times higher in males than females. Prostate cancer mortality was highest in black individuals/African Americans and began increasing after 2015. Bladder cancer mortality decreased significantly in White individuals, Black individuals, African Americans, and Asians/Pacific Islanders but remained stable in American Indian/Alaska Natives. Kidney cancer-related mortality was highest in White individuals but declined significantly in other races. Testicular cancer mortality increased significantly in White individuals but remained stable in Black individuals and African Americans. Genitourinary cancer mortality decreased in metropolitan areas but either increased (bladder and testicular cancer) or remained stable (kidney cancer) in non-metropolitan areas. Prostate and kidney cancer mortality was highest in the Midwest, bladder cancer in the South, and testicular cancer in the West.DiscussionSignificant sociodemographic disparities exist in the mortality trends of genitourinary cancers in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by genitourinary cancers.

Objective: To assess the extent of early mortality and its temporal course after prostatectomy and radiotherapy in the general population.Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database and East German epidemiologic cancer registries were used for the years 2005–2013. Metastasized cases were excluded. Analyzing overall mortality, year-specific Cox regression models were used after adjusting for age (including age squared), risk stage, and grading. To estimate temporal hazards, we computed year-specific conditional hazards for surgery and radiotherapy after propensity-score matching and applied piecewise proportional hazard models.Results: In German and US populations, we observed higher initial 3-month mortality odds for prostatectomy (USA: 9.4, 95% CI: 7.8–11.2; Germany: 9.1, 95% CI: 5.1–16.2) approaching the null effect value not before 24-months (estimated annual mean 36-months in US data) after diagnosis. During the observational period, we observed a constant hazard ratio for the 24-month mortality in the US population (2005: 1.7, 95% CI: 1.5–1.9; 2013: 1.9, 95% CI: 1.6–2.2) comparing surgery and radiotherapy. The same was true in the German cohort (2005: 1.4, 95% CI: 0.9–2.1; 2013: 3.3, 95% CI: 2.2–5.1). Considering low-risk cases, the adverse surgery effect appeared stronger.Conclusion: There is strong evidence from two independent populations of a considerably higher early to midterm mortality after prostatectomy compared to radiotherapy extending the time of early mortality considered by previous studies up to 36-months.

The global market for LHRH agonists for prostate cancer treatment is experiencing robust growth, driven by rising prevalence of prostate cancer, an aging global population, and the increasing adoption of LHRH agonists as a first-line treatment option. While precise market size data for 2025 is not provided, based on industry reports and considering a plausible CAGR of 7% (a conservative estimate given the market dynamics), we can project a market size of approximately $3.5 billion in 2025. This figure is an informed projection and not a precise figure derived from provided data. The market is segmented by application (age groups 55-75 and >75), type of LHRH agonist (Leuprolide, Goserelin, Triptorelin, and Others), and geography. The segments for patients aged 55-75 and >75 represent significant portions of the overall market, reflecting the age-related increase in prostate cancer incidence. Leuprolide currently holds the largest market share among the various LHRH agonists due to its established efficacy and widespread availability. However, other agonists are gaining traction, particularly those with improved delivery systems and reduced side effects. The projected CAGR suggests a continued expansion of the market through 2033. The North American and European regions currently dominate the LHRH agonist market for prostate treatment, due to high healthcare expenditure, advanced healthcare infrastructure, and high prevalence of prostate cancer. However, emerging markets in Asia-Pacific (particularly China and India) are demonstrating significant growth potential, driven by rising healthcare awareness, increased disposable incomes, and expanding access to advanced medical technologies. Market restraints include the potential for side effects associated with LHRH agonist therapy, the emergence of alternative treatment modalities, and price sensitivity in certain regions. However, ongoing research and development efforts focused on improving drug delivery and mitigating side effects are expected to further propel market growth. Key players in the market, such as AbbVie, Astella, Johnson & Johnson, Sanofi, and Merck Group, are investing heavily in research and development, and strategic partnerships to consolidate their market positions and expand their product portfolios.

In 2021, only 26 percent of survey respondents who were aged 50 to 64 years had a prostate-specific antigen (PSA) test that screened for prostate cancer in the past year. Prostate cancer is the most common type of cancer among men in the United States. This statistic shows the percentage of men aged 50 years and older who had a prostate cancer test in the U.S. in the past year as of 2021, by age.

The global prostate cancer diagnostics market is experiencing robust growth, driven by rising prevalence of prostate cancer, advancements in diagnostic technologies, and increasing awareness about early detection. The market, estimated at $8 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated value of $14 billion by 2033. This growth is fueled by several factors. Firstly, the aging global population contributes significantly to the increasing incidence of prostate cancer, creating a larger target market for diagnostic solutions. Secondly, technological advancements such as improved imaging techniques (MRI, PET scans), more sensitive biomarker tests (PSA tests, genomic assays), and minimally invasive biopsy procedures are enhancing diagnostic accuracy and early detection capabilities. Thirdly, increased healthcare expenditure and government initiatives promoting cancer screening and awareness programs are creating favorable market conditions. However, the market faces certain restraints. High costs associated with advanced diagnostic procedures, particularly genomic and molecular tests, can limit accessibility, especially in low- and middle-income countries. Additionally, challenges related to the interpretation of test results and potential for false positives or negatives can affect patient management and treatment decisions. Market segmentation reveals that the "tumor biomarker tests" segment holds a significant share, driven by the increasing adoption of advanced molecular diagnostics. Within application segments, the "age 55-75" group represents the largest segment, aligning with the peak incidence age for prostate cancer. Key players such as OPKO, Genomic Health, Abbott, and Roche are strategically investing in R&D and expanding their product portfolios to capitalize on the growing market opportunities. Geographical analysis indicates strong growth in North America and Europe, reflecting advanced healthcare infrastructure and higher awareness levels.

From 2003 to 2016, the 10-year relative survival rate after diagnosis for men aged 60 to 64 years with prostate cancer was around 98.7 percent in the United States. This statistic illustrates the relative survival of men with prostate cancer after diagnosis in the United States from 2001 to 2016, by age.

ObjectivesIn the US, the most common type of cancer and the second leading cause of cancer-related death in men is prostate cancer (PCa). Food and lifestyle factors may influence the risk of developing prostate cancer. Therefore, research on dietary components associated with prostate cancer is essential for its prevention. Data from the National Health and Nutrition Examination Survey (NHANES) between 2003 and 2010 was used for this cross-sectional investigation involving 5,658 middle-aged and older American men.MethodsDietary antioxidant vitamins A, C, E, total carotenoids, zinc, and selenium were subtracted from the total mean, divided by the standard deviation, respectively, and then summed to become the CDAI. Participants were categorized as high risk for PCa if they had tPSA greater than 10 ng/mL or tPSA levels between 4 and 10 ng/mL with f/t PSA ratios of 25% or below; the remaining subjects were classified as being at low risk for PCa.ResultsThe sample represented approximately 75,984,602 American men. After multivariate logistic regression, dose-effect analysis and stratified analysis, CDAI was significantly and linearly negatively associated with a high risk of prostate cancer (OR=0.95, P=0.002, P for linear=0.0021). Age moderation analysis showed a significant effect on the inverse relationship between CDAI and prostate cancer risk (B = -0.0097, SE = 0.0034, t = -2.85, P = 0.004). Among the independent effects of CDAI components, zinc and selenium were more strongly negatively associated with prostate cancer (zinc, OR = 0.80, P = 0.008; selenium, OR = 0.78, P< 0.001).ConclusionsCDAI serves as a dietary indicator of prostate cancer risk in middle-aged and older men, and high dietary antioxidant intake has a significant protective effect on prostate cancer risk, especially in the older population of men.

Advanced Prostate Cancer Drug Market Outlook

The global advanced prostate cancer drug market size was estimated to be around $9.5 billion in 2023, and it is projected to reach approximately $19.8 billion by 2032, growing at a compound annual growth rate (CAGR) of about 8.2% during the forecast period. The significant growth in this market is primarily driven by the increasing prevalence of prostate cancer, advancements in medical technologies, and rising awareness about the benefits of early diagnosis and treatment.

One of the key growth factors of the advanced prostate cancer drug market is the rising incidence rate of prostate cancer worldwide. Prostate cancer is one of the most common types of cancer among men, with a growing number of cases being diagnosed each year. Factors such as aging populations, lifestyle changes, and genetic predispositions contribute to the increasing incidence. Healthcare systems around the world are becoming more adept at early detection and diagnosis, which subsequently boosts the demand for advanced prostate cancer treatments.

Another significant growth driver is the continuous advancements in medical technology and pharmaceutical research. The development of innovative drugs and therapies, such as hormonal therapy, immunotherapy, and targeted therapy, has significantly improved the treatment outcomes for patients with advanced prostate cancer. These cutting-edge treatments offer better efficacy and fewer side effects compared to traditional chemotherapy, encouraging more patients and healthcare providers to opt for them. Furthermore, ongoing clinical trials and research activities are likely to introduce new and effective treatment options, further propelling the market growth.

Moreover, increased awareness and educational campaigns about prostate cancer screening and early treatment have played a crucial role in market expansion. Governments, non-profit organizations, and healthcare institutions are actively involved in spreading awareness about the importance of regular prostate cancer screenings, particularly for men over the age of 50. These initiatives help in the early detection of the disease, enabling timely intervention and treatment with advanced prostate cancer drugs. Additionally, the availability of financial assistance programs and insurance coverage for prostate cancer treatment further supports market growth.

Regionally, North America holds the largest share in the advanced prostate cancer drug market, owing to the high prevalence of the disease and the presence of well-established healthcare infrastructure. The region benefits from significant investments in research and development, leading to the early adoption of innovative therapies. On the other hand, the Asia Pacific region is expected to exhibit the highest growth rate during the forecast period. Factors such as improving healthcare facilities, rising awareness about prostate cancer, and increasing healthcare expenditure contribute to the market growth in this region. Europe, Latin America, and the Middle East & Africa also present promising growth opportunities, driven by increasing incidence rates and improving healthcare access.

Drug Type Analysis

Hormonal therapy remains one of the most widely used treatments for advanced prostate cancer. This therapy works by reducing the levels of male hormones (androgens) that can stimulate the growth of prostate cancer cells. Drugs like LHRH (luteinizing hormone-releasing hormone) agonists and antagonists are commonly used in hormonal therapy. These drugs effectively lower testosterone levels, thereby slowing the progression of the disease. The acceptance of hormonal therapy is further bolstered by its relatively lower side effect profile compared to other treatment options, making it a preferred choice for many patients and healthcare providers.

Chemotherapy is another critical segment within the advanced prostate cancer drug market. This treatment involves the use of powerful drugs to kill rapidly growing cancer cells. Chemotherapy is often employed when prostate cancer has spread to other parts of the body and is no longer responding to hormonal therapy. Drugs such as docetaxel and cabazitaxel are commonly used in chemotherapy regimens for advanced prostate cancer. Despite its effectiveness, chemotherapy is associated with significant side effects, which can impact the patient's quality of life. Nonetheless, it remains a vital treatment option for aggressive and advanced stages of prostate cancer.

Immunotherapy has emerged as a promising treatment for advanced pr

This record contains raw data related to article “Assessing the Role of High-resolution Microultrasound Among Naïve Patients with Negative Multiparametric Magnetic Resonance Imaging and a Persistently High Suspicion of Prostate Cancer"

Abstract

ObjectivesIn the US, the most common type of cancer and the second leading cause of cancer-related death in men is prostate cancer (PCa). Food and lifestyle factors may influence the risk of developing prostate cancer. Therefore, research on dietary components associated with prostate cancer is essential for its prevention. Data from the National Health and Nutrition Examination Survey (NHANES) between 2003 and 2010 was used for this cross-sectional investigation involving 5,658 middle-aged and older American men.MethodsDietary antioxidant vitamins A, C, E, total carotenoids, zinc, and selenium were subtracted from the total mean, divided by the standard deviation, respectively, and then summed to become the CDAI. Participants were categorized as high risk for PCa if they had tPSA greater than 10 ng/mL or tPSA levels between 4 and 10 ng/mL with f/t PSA ratios of 25% or below; the remaining subjects were classified as being at low risk for PCa.ResultsThe sample represented approximately 75,984,602 American men. After multivariate logistic regression, dose-effect analysis and stratified analysis, CDAI was significantly and linearly negatively associated with a high risk of prostate cancer (OR=0.95, P=0.002, P for linear=0.0021). Age moderation analysis showed a significant effect on the inverse relationship between CDAI and prostate cancer risk (B = -0.0097, SE = 0.0034, t = -2.85, P = 0.004). Among the independent effects of CDAI components, zinc and selenium were more strongly negatively associated with prostate cancer (zinc, OR = 0.80, P = 0.008; selenium, OR = 0.78, P< 0.001).ConclusionsCDAI serves as a dietary indicator of prostate cancer risk in middle-aged and older men, and high dietary antioxidant intake has a significant protective effect on prostate cancer risk, especially in the older population of men.

The global radioactive seed implant needle market is experiencing robust growth, driven by the increasing prevalence of prostate cancer and other cancers requiring brachytherapy. The market size in 2025 is estimated at $350 million, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by advancements in needle technology leading to improved precision and reduced invasiveness during implantation procedures. Furthermore, the rising adoption of brachytherapy as a minimally invasive treatment option, coupled with technological innovations in seed delivery systems, significantly contributes to market expansion. The increasing number of specialized hospitals and surgical centers equipped to perform brachytherapy procedures further bolsters market demand. The market is segmented by needle type (preloaded and loose seed needles) and application (surgery centers, hospitals, and specialty clinics). Preloaded needles are projected to dominate due to their ease of use and reduced risk of seed misplacement. Hospitals currently represent the largest segment by application, but the growth of specialized clinics is anticipated to drive market share diversification in the coming years. Geographic segmentation reveals strong growth prospects in North America and Europe, driven by established healthcare infrastructure and high cancer incidence rates. However, developing economies in Asia-Pacific are anticipated to witness significant growth potential due to rising healthcare expenditure and increased awareness of minimally invasive treatment options. While regulatory hurdles and high treatment costs may pose some challenges, the overall market outlook remains positive, driven by consistent technological advancements and a growing need for effective cancer treatment modalities. The market's steady growth is further supported by ongoing research and development efforts focused on improving the efficacy and safety of radioactive seed implantation. This includes the development of novel seed materials with enhanced radiation properties and the integration of advanced imaging techniques for precise seed placement. Furthermore, the increasing awareness among healthcare professionals and patients regarding the benefits of brachytherapy, including reduced side effects and shorter recovery times compared to traditional treatments, is driving market expansion. The growing geriatric population, coupled with the rising incidence of age-related cancers, is expected to further fuel market demand in the coming years. While the competition among established players remains intense, the emergence of innovative technologies and new market entrants will continue to shape the market landscape, creating both opportunities and challenges for all stakeholders involved in this crucial field of medical technology.

In 2022, the cancer type with the highest age-standardized incidence rate in Latin America and the Caribbean was prostate cancer with 57.5 new cases per 100,000 population. It was followed by breast cancer, with an incidence rate of nearly 52 people per 100,000 population. That year, prostate cancer was the type of cancer with the highest mortality rate in the region.